Posted by Michael Wonder on 18 Aug 2023
Forxiga approved in China to reduce the risk of cardiovascular death and hospitalisation in adult patients with symptomatic chronic heart failure
18 August 2023 - The first and only heart failure therapy with a proven mortality benefit now approved for patients with heart failure regardless of ejection fraction status.
Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for heart failure, or urgent heart failure visits in adults with symptomatic chronic heart failure.
